Header Logo

Connection

Mary Jo Fidler to Tumor Microenvironment

Back to Details
This is a "connection" page, showing publications Mary Jo Fidler has written about Tumor Microenvironment.
Mary Jo Fidler
Connection Strength
0.054
Tumor Microenvironment
  1. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
    View in: PubMed
    Score: 0.054
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.